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Background: Venous leg ulcers are a growing socioeconomic burden. Pale sulfonated shale oils (PSSO) are used for
therapy of inflammatory skin diseases and have been shown to enhance wound healing in vitro and in vivo. The aim of this
study was to investigate whether PSSO is capable of enhancing venous ulcer healing beyond compression therapy alone.
Methods: One hundred nineteen patients were enrolled in this randomized, multicenter, observer-blind study. In the
treatment group, PSSO 10% was applied daily for 20 weeks, and the control group received the vehicle only. Wounds were
covered by a nonadherent gauze dressing, and compression therapy with short-stretch elastic bandages was performed in
an outpatient setting. The primary study end point was defined as cumulative reduction in wound area; the secondary
study end point was treatment success as assessed by both physicians and patients. Additionally, adverse events, including
changes with respect to physical examination and vital signs, were documented.
Results: At the end of the study period, ulcer size was significantly more reduced in the PSSO group compared with the
vehicle group (15  15.9 to 6.2  12.9 cm2 vs 11.4  14.5 to 10.8  15.7 cm2; P  .0005). The cumulative relative
reduction in ulcer area was significantly higher in the PSSO group (4391  4748.7 vs 231.9  6283.6 %  days; P
< .0001). Relative reduction in wound area was significantly greater in the PSSO group as early as 6 weeks after the
beginning of treatment (47.4 28.4 vs23.8 42.2%; P< .001). PSSO was judged successful both by physicians and
patients. There were no significant differences in adverse events (PSSO, 9 [12.2%]; vehicle, 7 [11.1%]. Similarly,
tolerability of PSSO was equal to the tolerability of the vehicle.
Conclusion: Pale sulfonated shale oils were capable of favoring venous ulcer healing in addition to compression therapy.
PSSO should be considered for future wound care protocols for treatment of venous leg ulcers. ( J Vasc Surg 2006;43:
94-100.)Leg ulcerations are a common problem in the Western
world, affecting about 1% of the population at some time of
their life.1-3 Approximately 70% of all lower-extremity leg
ulcers are caused by chronic venous insufficiency (CVI).4
The cornerstones of care consist of the application of gauze
dressings and compression therapy.5-7 However, venous
ulcers are often large in size, extremely painful, and have a
poor prognosis and high recurrence rates.8,9 So far, no
topical agent is accepted for standard wound care protocols
in venous leg ulcers.8,10
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94Sulfonated shale oils (bituminosulfonates) are extracted
from sulfur-rich oil shale, a widespread sedimentary rock.
Purification by distillation results in two oil fractions: a
light-colored, pale sulfonated shale oil (PSSO) is produced
from the low-boiling fraction and a dark sulfonated shale oil
from the high-boiling fraction. Dark sulfonated shale oil
was first introduced for treatment of skin diseases by Unna
in 1882.11 Clinical trials and toxicologic studies have dem-
onstrated that both variants are safe and well tolerated.12,13
Pale sulfonated shale oil is already accepted for therapy
of inflammatory skin diseases, psoriasis, and seborrhoic
eczema.13-15 The active ingredients of PSSO exhibit an-
tiphlogistic, analgetic, and antibacterial properties.16,17
PSSO was recently shown to be capable of enhancing
proliferation and growth factor expression of keratinocytes
in vitro and stimulating wound healing in vivo, measured as
epithelization.18 The aim of this study was to evaluate
whether the topical application of PSSO in addition to
compression therapy and standard moist wound care favors
venous ulcer healing.
PATIENTS AND METHODS
Between October 2002 and June 2004, 119 patients
were enrolled in this randomized, multicenter, observer-
blinded, controlled trial conducted in 13 outpatient wound
clinics in Germany and Slovakia (see Appendix). The study
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sinki and the Guidelines for Good Clinical Practice. Proto-
col and informed consent procedures were approved by
each center’s ethics committee.
Patients. Patients aged 18 years with leg ulcers 3
cm2 owing to CVI were eligible for the investigation.
Exclusion criteria were defined as ulcerations not due to
CVI, severe cardiac, respiratory, gastrointestinal, liver, or
renal disease; malignancy, or signs of wound infection.
Pregnant women or nursing mothers were excluded.
Venous status was assessed by a duplex ultrasound scan
that showed valvular incompetence or reflux in the super-
ficial or deep veins. Arterial occlusive disease was excluded
by measuring the ankle-brachial pressure index (ABI), with
an ABI0.8 defined as inclusion criteria. During the study
period, no venous surgery was performed on any patient.
Before randomization, patient eligibility for the study
was assessed through a 2-week screening period in which
demographic data, medical history, and baseline informa-
tion were recorded. During this time, ulcers were treated
with standard care and compression therapy. After the
screening period, patients were randomized to one of the
treatment groups by using a centralized computer system
with block randomization (1:1) (RanCode, IDV, Gauting,
Germany). Investigators were blinded to the randomiza-
tion process to eliminate bias.
During follow-up visits, which were performed in bi-
weekly intervals, the following parameters were measured
and recorded:
● ulcer pain was assessed by patients on a 10-cm visual
analogue scale from 0 (no pain) to 10 (maximum
pain);
● the extent of fibrinous discharge, defined as yellow
eschar, was classified as “none, medium, or complete”;
and
● the presence or absence of necrotic tissue was
documented.
Additionally, treatment success and tolerability were
judged by physicians and patients on a five-point qualitative
scale with categories of “very good, good, medium, mod-
erate, and bad.” Treatment success was defined by the
subjective assessment of response to treatment relative to
the baseline. Tolerability was defined as local wound dis-
comfort relative to the baseline, including itching, ery-
thema, burning, dryness, or swelling. Adverse events in-
cluded changes with respect to physical examination and
vital signs.
Relative reduction in wound area (Ri) was calculated as
Ri 100 (Ai – Abaseline)/Abaseline where A equals wound
area and i equals number of visits. Cumulative relative
reduction in ulcer area was calculated as area under baseline
(AUB)   visit interval i  1  (Ri  Ri  1)/2.
It was determined in advance that a 120-patient study
was of sufficient size to provide the required information.
Based on the assumption that approximately 95% of the
subjects in the treatment group would show complete
granulation of the wound by the end of the 20-weektreatment period compared with 75% of the subjects in the
vehicle group, a sample size of 65 patients per group would
provide 90% power to detect a significant difference in
primary study end points at a 5% significance level.
Local treatment. Patients were randomized into
two groups treated either with 10% Leukichtan, a PSSO
gel, (Ichthyol-Gesellschaft, Hamburg, Germany) (PSSO
group) or the vehicle. The vehicle consisted of a nonionic
polyoxyethylene-polyoxypropylene block copolymer with the
general formulaHO(C2H4O)a(-C3H6O)b(C2H4O)aH pro-
viding the gel component of Leukichtan. PSSO 10% or the
vehiclewas administered directly onto thewound surface daily
as a 2- to 2.5-mm-thick gel layer. Wounds were covered by
Jelonet, a nonadherent gauze dressing (Smith & Nephew
Medical, Lohfelden, Germany), and compression therapy was
performed throughout the entire study in both groups by
using short-stretch elastic bandages (Pütter-Bandages, Hart-
mann, Germany). Prescription footwear was used for pressure
relief if necessary.
Clinical parameters, ulcer measurement and ulcer
size stratification. Baseline wound size was calculated
before randomization by measuring the maximum length
and breadth and multiplying them. Patients were examined
every 2 weeks. At every visit, ulcer area was assessed by
photoplanimetry. The ulcer outline was traced on Opsite
transparent paper (Smith & Nephew Medical), and area
was calculated in a blinded manner using a standardized
computer system.19
Study end points. The primary end points of the
study were (1) cumulated relative reduction in ulcer area
and (2) complete granulation and epithelization of the
wound by the end of the 20-week treatment period. Com-
plete healing of the wound was defined as complete epithe-
lization. Secondary end points were time courses for (1)
pain, (2) necrotic wound tissue, (3) fibrinous discharge, (4)
treatment success, and (5) tolerability.
Statistics. Block randomization (1:1) was chosen and
calculated with the validated program RanCode. Data rep-
resent mean  standard deviation (SD). Comparison of
baseline variables was performed by using analysis of vari-
ance (ANOVA) and 2 test. Differences in end point vari-
ables between treatment groups were calculated using
ANOVA (relative reduction in ulcer area) and the log-rank
test (time to complete granulation and epithelization).
Analysis of secondary end point parameters was performed
with ANOVA, the 2 test (dichotomous data), and the
Mantel-Haenszel test (assessment of treatment success).
P  0.05 was considered significant.
RESULTS
Baseline data. One hundred thirty-seven patients
were assessed for eligibility. Ultimately, 119 patients were
enrolled in the study; 62 were randomized to PSSO 10%
and 57 to vehicle treatment. Eighteen (15%) of the 119
patients—nine each in the in the PSSO 10% and vehicle
groups—did not complete the study for other reasons than
ulcer healing. These patients were included in data analysis
with their assigned group (Fig 1).
w th
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duration, wound size, pain score, and wound stratification;
however, patients in the PSSO group had a significantly
increased weight. Both groups had comparable superficial
or deep venous insufficiency and insufficiency of perforat-
ing veins. Significantly more patients were suffering from
post-thrombotic changes in the PSSO group compared
with the vehicle group (Table I). Additionally, wounds
were comparable for granulation, epithelization, and the
amount of fibrinous discharge or necrotic tissue (Table II).
Study end points. At the end of the study period,
ulcer size was significantly more reduced in the PSSO group
compared with the vehicle group (15  15.9 to 6.2  12.9
cm2 vs 11.4  14.5 to 10.8  15.7 cm2; P  .0005) (Table
III). Cumulative relative reduction in ulcer area was signif-
icantly greater in the PSSO group compared with the
vehicle group (	4391 4748.7 vs	231.9 6283.6 %
days; P  .0001). Relative reduction in wound area as-
sessed at every visit showed that as early as 6 weeks after the
beginning of treatment, the reduction in wound area was
significantly increased in the PSSOgroup comparedwith the
Fig 1. Patient flovehicle group (	47.4 28.4 vs	23.8 42.2%; P  .001)(Fig 2). There was no difference in groups regarding
complete epithelization or granulation. After 20 weeks
of treatment, 33 patients (53.2%) in the PSSO group
showed complete granulation, and 21 patients (33.9%)
had complete epithelization. In the vehicle group, 21
patients (36.8%) developed complete granulation (P 
.161), and 13 patients (22.8%) had complete epitheliza-
tion (P  .177).
Throughout the entire observation period there was no
significant difference in pain score between the groups
(baseline, 4.6  2.9 vs 5.3  3.2; study end point, 1.8 
2.3 vs 2.6 2.4). Additionally, wounds in both groups did
not show a significant difference in the presence of fibrinous
discharge or necrotic tissue.
Treatment success of PSSO 10% compared with vehicle
was assessed at every visit both by physicians and patients
(Table IV). After 20 weeks of treatment, physicians and
patients thought PSSO 10% to be significantly more effec-
tive than therapy with vehicle alone (P  .001; P  .001).
There were no significant differences in adverse events
between groups (PSSO, 9 [12.2%]; vehicle, 7 [11.1%]). At
rough the study.the end of the investigation, tolerability of PSSO 10% was
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physicians and by patients (Table V).
DISCUSSION
Several topical agents were investigated as adjuvant
therapy for venous leg ulcers. However, none of them
could be proven effective in clinical practice.20-22 Apligraf
(Graftskin, Orangogenisis, Inc, Canton,Mass), a living skin
equivalent, has been shown to accelerate wound closure in
hard-to-heal venous leg ulcers, but it is no longer available
on the European market.23 So far, compression therapy and
moist wound care are still the gold standard in the treat-
ment of venous leg ulcerations.6,7,24,25
With this prospective, multicenter, randomized, and
observer-blind study, we describe an enhancement of ve-
nous ulcer healing by a topical agent in addition to standard
care consisting of compression therapy. The groups had
highly comparable baseline and demographic characteris-
tics. It was noticeable that patients in the PSSO group were
significantly heavier (P .004); however, there are reports
that obesity does not affect venous ulcer healing.26 The
higher weight of the PSSO group even strengthens our
results.
Additionally, wound duration and actual healing status
were comparable, because there was no significant differ-
ence in the presence of fibrinous discharge or necrotic
tissue and the percentage of epithelization and granulation
were equal. The relative reduction in ulcer area was signif-
icantly increased by treatment with PSSO 10% compared
Table I. Main demographic and clinical characteristics
at baseline*
10% PSSO
(n  62)
Vehicle
(n  57) P
Sex 1.0
Male 20 (32.3) 19 (33.3)
Female 42 (67.7) 38 (66.7)
Age (years) 66.8  13.7 70.6  11.1 .1
Weight (kg) 88.7  19.2 79.4  14.6 .004
Height (cm) 169.5  8.7 167.8  7.7 .26
Wound duration (months) 24.9  51.2 17.8  18.4 .32
Wound size (cm2) 26.2  49.0 17.2  21.0 .26
Wound stratification .36
20 cm2 48 (77.4) 50 (87.7)
20 but 35 cm2 7 (11.3) 3 (5.3)
35 cm2 7 (11.3) 4 (7)
Venous disease
Superficial reflux 17 (27.4) 25 (43.9) .110
Deep reflux 1 (1.6) 2 (3.5) 1.00
Perforator vein
insufficiency 9 (14.5) 8 (14.0) 1.00
Post-thrombotic
syndrome 35 (56.5) 22 (38.6) .037
CEAP class
C6 62 (100) 57 (100)
Pain score 4.6  2.9 5.3  3.2 .22
PSSO, Pale sulfonated shale oil.
*Data are expressed as mean  SD and n (%); P  .05 was considered
significant.with the vehicle. This effect was seen as early as 6 weeks afterthe beginning of treatment and was sustained throughout the
entire observation period.
There was no significant difference, however, regarding
complete epithelization and granulation. Complete heal-
ing, defined as complete epithelization, was observed in
33.9% in the PSSO group and in 22.8% in the vehicle
group. After 20 weeks of treatment, wounds in the PSSO
group were smaller but showed an equal extent of granu-
lation tissue and epithelization. These results are compara-
ble to other studies in the literature, especially where
wound duration and initial wound area are concerned. It is
well known that large venous ulcers (12 cm2) and ulcers
with long duration show poor healing.9,27 Additionally,
the high percentage of post-thrombotic changes in both
groups might provide another possible explanation for the
relatively low rates of complete epithelization reported in
our study.
Although healing, defined as complete epithelization,
was not different between both groups at the end of the
observation period, we believe that the significant reduc-
tion in wound size found for the PSSO group has a clinical
relevance, as Gelfand et al28 showed the percentage change
in wound area as a valid surrogate marker for complete
Table II. Wound characteristics at baseline*
10% PSSO
(n  62)
Vehicle
(n  57)
Signs of granulation in the
wound bed
Yes 32 (51.6) 29 (50.9)
No 30 (48.4) 28 (49.1)
Signs of epithelization at
the wound margins
Yes 7 (11.3) 7 (12.3)
No 55 (88.7) 50 (87.7)
Fibrinous tissue
Yes 45 (72.6) 35 (61.4)
No 17 (27.4) 22 (38.6)
Necrotic tissue
Yes 7 (11.3) 3 (5.3)
No 55 (88.7) 54 (94.7)
PSSO, Pale sulfonated shale oil.
*Data are given as n (%); P was not significant for all data.
Table III. Ulcer area assessed by photoplanimetry before
treatment and at the end of the study and relative change
in ulcer area*
10% PSSO
(n  62)
Vehicle
(n  57) P
Initial ulcer area before
treatment (cm2) 15.0  15.9 11.4  14.5 .20
Final ulcer area (cm2) 6.2  12.9 10.8  15.7 .0005
Relative change in ulcer
area (%) 	72.0  37.2 	18.7  68.1 .0001
PSSO, Pale sulfonated shale oil.
*Data are given as mean  SD. P  .05 was considered significant.healing of venous ulcers. The implication is also that epi-
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both groups if our study had been prolonged to a longer
observation period.
When sulfonated shale oils were first introduced by Unna
in 1882, they were mainly used for the treatment of inflam-
matory skin diseases.11 Venous ulcers are also characterized by
a chronic inflammatory statewith long-standing inflammatory
cellular infiltrates and elevated levels of proinflammatory cyto-
kines in their wound fluid.29 In addition, the cellular environ-
Fig 2. Relative reduction in wound area during trea
significantly increased in the pale sulfonated shale oil (PS
was sustained throughout the entire observation period.
variance).
Table IV. Assessment of treatment success at the end of
the study (20 weeks)*
10% PSSO
(n  62)
Vehicle
(n  57) P
Physician .001
Missing 16 (25.81) 21 (36.84)
Very good 25 (40.32) 9 (15.79)
Good 11 (17.74) 5 (8.77)
Medium 5 (8.06) 11 (19.3)
Moderate 3 (4.84) 7 (12.28)
Bad 2 (3.23) 4 (7.02)
Patient .001
Missing 16 (25.81) 21 (36.84)
Very good 26 (41.94) 7 (12.28)
Good 11 (17.74) 10 (17.54)
Medium 6 (9.68) 10 (17.54)
Moderate 1 (1.61) 6 (10.53)
Bad 2 (3.23) 3 (5.26)
PSSO, Pale sulfonated shale oil.
*Data are given as n (%). Differences between groups were calculated by the
Mantel-Haenszel test, with P  .05 considered significant.ment becomes less inflammatory as the wound heals.30 PSSOexhibits a markedly anti-inflammatory action comparable
with 0.5% hydrocortisone.16 In vitro, PSSO has been shown
to inhibit cytokine production of leukocytes and leukocyte
migration.31,32 Similarly, bituminosulfonates have been
proven antibacterial through in vitro tests.33 This might be
another mechanism of action, because healing slows
down in proportion to the bacterial burden of a
wound.34 There is a growing body of evidence that
bacteria present in chronic wounds delay healing even in
t. After 6 weeks, relative reduction in wound size is
group compared with the vehicle group. This difference
shown are  standard deviation. *P  .001 (analysis of
Table V. Assessment of tolerability at the end of the
study (20 weeks)*
10% PSSO
(n  74)
Vehicle
(n  63) P
Physician .077
Missing 27 (36.49) 27 (42.86)
Very good 29 (39.19) 17 (26.98)
Good 16 (21.62) 14 (22.22)
Medium 2 (2.70) 4 (6.35)
Moderate 0 (0) 1 (1.59)
Bad 0 (0) 0 (0)
Patient .154
Missing 27 (36.49) 27 (42.86)
Very good 25 (33.78) 15 (23.81)
Good 19 (25.68) 16 (25.40)
Medium 2 (2.70) 3 (4.76)
Moderate 1 (1.35) 1 (1.59)
Bad 0 (0) 1 (1.59)
PSSO, Pale sulfonated shale oil.
*Data are given as n (%). Differences between groups were calculated by the
Mantel-Haenszel test, with P  .05 considered significant.tmen
SO)
Datathe absence of the typical clinical signs of infection.34
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a biofilm that provides protection from host defense
mechanisms.
Bituminosulfonates were previously demonstrated as safe
and well-tolerated agents in the therapy of skin diseases. 12,15
Similarly in this study, there was not a significant greater
number of adverse events during treatment with PSSO 10%
compared with vehicle. Four patients, two each in the
PSSO and vehicle groups (2.7%), had eczema and pruritus.
No severe side effects were reported throughout the entire
study period. At the end of the study, both physicians and
patients assessed PSSO 10% significantly superior to vehi-
cle. Both thought PSSO 10% to bemore effective regarding
treatment success with equal tolerability compared with
vehicle treatment.
CONCLUSION
With this randomized, controlled, observer-blind, mul-
ticenter study, we demonstrated pale sulfonated shale oil is
capable of favoring venous ulcer healing beyond compres-
sion therapy alone. Additionally, the new agent was safe
and well tolerated. Pale sulfonated shale oil should be
considered for future wound care protocols in the treat-
ment of chronic venous leg ulcers.
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